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ABSTRACT 
OBJECTIVES: To assess the efficacy, safety and tolerability of T. 
methotrexate 15mg/wk and T.azathioprine 50mg/day  in chronic plaque 
psoriasis. 
INTRODUCTION:  
Psoriasis is a common, chronic, and recurrent inflammatory disease of the skin. 
It has a tendency to wax and wane with flares related to systemic or 
environmental factors including life stress events and infection. Psoriasis is 
characterised by the infiltration of skin by activated T cells and an abnormal 
proliferation of keratinocytes. A classic lesion of psoriasis is characterised by 
well demarcated, raised, red plaques of varying sizes with a white scaly surface. 
Psoriasis also shows its impact on quality of life and potentially long term 
survival. 
 
Methotrexate:  Methotrexate has a greater affinity for  dihydrofolic  acid 
reductase  than has folic acid. The synthesis of  DNA is blocked  when 
dihydrofolic  acid  reductase is bound and thereby cell division is  reduced. 
Methotrexate may also affect the inflammatory element of psoriasis. 
 
Azathioprine: Azathioprine is an immunosuppressive drug which is converted 
non-enzymatically in the body to  6-mercaptopurine  (6-MP), then by 
hypoxanthine guanine  phosphoribosyl  transferase (HGPRT) to 6-thioguanine 
nucleotides. Their immunosuppressive activity results from disruption of 
normal DNA and RNA synthesis. Additionally, an imidazole metabolite appears 
to have powerful anti-inflammatory  properties. 
 
METHODS AND MATEIALS: 
 
PLACE OF STUDY  : Govt. Stanley medical college ,Chennai. 
TYPE OF STUDY :  RANDOMISED, PROSPECTIVE, OPEN LABEL,       
PARALLEL GROUP STUDY. 
TIME DURATION : One year.(June 2013 to May 2014) 
SAMPLE SIZE :  2 groups , each containing  20 patients. 
STUDY PROCEDURE: 
A brief and relevant medical history with physical examination will be taken at 
screening visit to ensure all the relevant eligibility criteria are met. After 
successful screening, patient would be randomised to one of the two treatment 
groups as follows, 
GROUP A: Patients who fulfil inclusion criteria and willing to take part in trial 
and sign consent letter would be included in the study. They would be 
administered T.METHOTREXATE 15mg/week for 12 weeks. Efficacy will be 
assessed by monitoring PASI score every week. Safety and tolerability 
monitored by complete hemogram weekly and liver function test biweekly. 
GROUP B:  Patients who fulfil inclusion criteria and willing to take part in trial 
and sign consent letter would be included in the study. They would be 
administered T.AZATHIOPRINE 50mg/day for 12 weeks. Efficacy will be 
assessed by monitoring PASI score every week. Safety and tolerability 
monitored by complete hemogram weekly and liver function test biweekly. 
 
CONCLUSION: Methrotrexate was found to be more efficacious than 
azathioprine in achieving PASI 75 at week 12. Both the drugs were safer and 
tolerable while remission period in the Methotrexate group was longer than 
Azathioprine group. 
KEY WORDS: Psoriasis, Methotrexate, Azathioprine 
INTRODUCTION 
Psoriasis is a genetically determined, chronic inflammatory and 
proliferative, intractable skin disorder in which both environmental and 
genetic factors play vital role. It can cause severe discomfort, 
disfigurement and psychological distress to the affected. 
Various treatment modalities for Psoriasis are available in this 
modern era. Treatment options usually based on the severity of disease, 
associated co-morbidities, efficacy and also patient preference. Severity 
of disease is clinically graded as mild to moderate, or moderate to 
severe. Patients with mild to moderate disease can be managed by 
topical therapy, while more severe disease requires systemic therapy. 
Psoriasis is a very difficult disease to manage because of its 
chronicity and frequently relapsing nature. So it requires long term use 
of systemic therapy to achieve adequate disease control. Though 
multiple systemic therapies are available at present, unmet needs remain 
for safe and long term treatment. 
Hence, researchers are concerned with finding new therapies for 
psoriasis that will be safe and efficacious. 
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REVIEW OF LITERATURE 
DEFINITION 
Psoriasis is ‘a common, chronic, disfiguring, inflammatory and 
proliferative condition of the skin, in which both genetic and 
environmental influences have a critical role. The most characteristic 
lesions consist of red, scaly, sharply demarcated, indurated plaques, 
present particularly over extensor surfaces and scalp. The disease is 
enormously variable in duration, periodicity of flares and extent. 
Morphological variants are common’[1]. 
EPIDEMIOLOGY 
PREVALENCE 
Psoriasis shows wide differences in prevalence among different 
races and in different regions of the world. It varies from 0.1% to 3% in 
different studies all over the world
[2-4]
. Influence of ethnic factors is also 
studied, which ranges from nil cases in somoan groups, South American 
Indians, aboriginal Australians to 12% in arctic Kasachye
[5]
. 
 
 
AGE OF ONSET 
Even though psoriasis can occur at any age, it has bimodal age of 
onset where the first peak is at 15-20 years of age and second one at  
55-60 years
[6]
. 
Henseler and Christophers demonstrated the existence of two 
distinct forms ofdisease, 
Type1-- hereditary, strongly HLA associated (particularly HLA-
Cw6), with an early onset (before the age of 40) and more likely to be 
severe and recurrent.  
Type II --sporadic, late onset, HLA unrelated, without any family 
history and has a good prognosis. 
FAMILAL OCCURENCE 
Kaur et al study shows the mean age of onset of disease is 23 
years in patients with family history as compared to 28 years in others.  
In a German study, risk to get psoriasis was 2% if no parent or 
sibling was affected. It was 6% if one sibling is affected.14% and 41% if 
one and both the parents were affected respectively
[7]
. 
 
SEX RATIO 
Both sexes are equally affected. But in most Indian studies, a 
higher prevalence has been noted in males. 
ETIOLOGY 
The exact etiology of Psoriasis is not known. But the following 
factors playa considerable role. 
o GENETIC 
o ENVIRONMENTAL  FACTORS 
ROLE OF GENETICS 
 Role of genetic factors is well recognized in psoriasis. 
 Danish twin study has shown the concordance rate among 
monozygotic twins as 64%, compared to 15% for dizygotic twins. 
 Genome-wide linkage scans have revealed at least 9 chromosomal 
loci with significant evidence for linkage to Psoriasis (PSORS1–
9)
[8]
. 
 The major Psoriasis genetic determinant is PSORS1, that accounts 
for 35–50% of the heritability of the disease. 
 Location of PSORS1 has been identified within the major 
histocompatibility complex (MHC) on chromosome 6p.  
 HLA associations in psoriasis- HLA-B13, HLA-B17, HLA-Cw6, 
HLA-DR7. HLA-B27, HLA-B38,-39, HLA-DR4 (psoriatic 
arthritis). Protective - HLA-B22. 
 
ENVIRONMENTAL FACTORS 
Several triggering factors have been identified, which induce or 
aggravate psoriasis in genetically predisposed individuals. They are as 
follows. 
Trauma 
Development of psoriasis at the site of trauma including physical, 
chemical, allergic, mechanical, electrical, infective, inflammatory,  
or surgical has been well recorded
[9]
. Isomorphic phenomenon 
(koebnerisation) at the site of sunburn, vaccination, insect/animal bite 
has been elicited. 
Infections 
Upper respiratory tract infection and tonsillitis, especially due to 
group A streptococci may play an important role in exacerbation of 
existing psoriasis or precipitate an attack of acute guttate psoriasis in 
predisposed persons
[10]
. 
HIV and Psoriasis 
Psoriasis and psoriatic arthropathy have been found to be 
associated with HIV
[11]
. The prognosis of acquired immune deficiency 
syndrome in psoriatic patients is poor. Immune dysregulation plays 
important role, although the exact mechanism of worsening is unclear. 
Complications like arthritis, dactylitis, enthesitis are commonly 
encountered in HIV individuals. 
Drugs 
Many drugs can precipitate the onset or exacerbations of 
Psoriasis. 
For example, lithium, beta blockers, angiotensin converting 
enzyme inhibitors, imiquimod, interferon-α and γ, non-steroidal anti-
inflammatory drugs, anti-malarials like chloroquine and sudden 
withdrawal of steroids. 
  
Seasonal variations 
Winter season usually worsens the situation in psoriasis because 
of high humidity. Sunlight improves psoriasis but worsens it in few
[12]
.  
Hormonal factors 
Psoriasis remains unaltered in 40% of pregnancies, improves in 
40%, but worsens in only 14%
 [13]
. This is due to high levels of IL-10 
which is an inhibitor of type I immune response. 
Precipitation of generalised pustular psoriasis during pregnancy 
has rarely been reported. 
The facts like early age of onset in women, peak around puberty, 
changes during pregnancy and exacerbation of psoriasis with high dose 
oestrogen therapy support the view of hormonal influences. 
 
Psychological factors 
Emotional stress has been identified as a key exacerbator or 
trigger of psoriasis in many patients. 
Exact pathogenesis is not fully understood. But increase in 
neuropeptides and beta-endorphin levels is believed to play the role. 
Alcohol and smoking 
Increased alcohol intake is a recognized stress response. 
Excessive drinking is a consequence of the disease and leads to 
treatment resistance and poor therapeutic compliance. 
Patients smoking more than 15 cigarettes/day had an odds ratio of 
10.5 for association with palmo-plantar pustulosis
[14]
. 
 
Obesity 
Obese  persons with psoriasis are more likely to present with 
severe form of disease. 
 
 
 
 
 
 
 
PATHOGENESIS 
The pathogenesis of Psoriasis is complex as multiple factors are 
involved. However both genetic and environmental factors are playing 
important role. HLA-association is invariably linked to type I plaque 
psoriasis and guttate psoriasis. 
The characteristic features in the pathogenesis of psoriasis, 
include epidermal hyper-proliferation, vascular changes, inflammation 
and other immunological changes. 
CELLULAR PARTICIPANTS 
Role of  T cells 
The subsets of T cells, especially CD4+ and CD8+ play 
predominant role. Location of  CD4+, CD8+  T cells is mainly seen in 
the epidermis and upper dermis respectively. T cells express cutaneous 
lymphocyte antigen (CLA) which is a ligand for E-selectin. Expression 
of E-selectin in skin vessels provides access to T cells to skin. 
Even though both Th1&2 play the role, Th1 mediated 
inflammation is considered to be more important. Production of IL-23, 
IL-17 may play a role in chronic inflammation in psoriasis. 
Natural killer- T cells 
NK cells are major producers of interferon-γ and act as a bridge 
between innate and acquired immunity. 
Killer immunoglobulin like receptors (KIRs), a regulator of NK 
cells can recognize HLA-C and MHC class I molecules. Association of 
KIR genes with psoriasis and psoriatic arthritis have been identified. 
Dendritic cells (DC) 
Constant communication of  T cells in psoriatic lesions with several 
subsets of dendritic cells have been demonstrated. 
1. Langerhans cells (LC) 
            Role of LC in psoriasis is still unclear. The numbers of LC are 
characteristically decreased in psoriasis and migration of these antigen 
presenting cells (APC) in response to inflammatory cytokines is also 
impaired in uninvolved epidermis. 
2. Inflammatory epidermal dendritic cells (IEDCs) 
Numbers of IEDCs are markedly increased in active lesions of 
psoriasis and other inflammatory dermatoses like eczema. But they are 
almost absent in normal skin. They are differentiated from LCs by the 
lack of Birbeck granules and decreased expression of CD1a. 
3. Dermal dendritic cells 
While expressing no activation markers in normal skin, 
expression of MHC class II/factor XIIIa can be seen in active psoriatic 
skin lesions. A marked increase in number and maturation state of these 
cells noted. 
4. Plasmacytoid dendritic cells (pDCs) 
pDCs are increased in both involved and uninvolved skin in 
psoriasis. They link innate and adoptive immunity and produce more 
amount of interferon-α. Imiquimod probably acts by binding to TLR7 
on pDCs and leads to exacerbation of psoriasis. 
 
Mast cells and macrophages 
Both mast cells and macrophages play prominent role in initial 
and developing lesions of psoriasis. Macrophages are present under the 
basement membrane, subjacent to proliferating keratinocytes. 
Expression of tumour necrosis factor-α by macrophages may play a key 
role. 
Neutrophils  
The number of neutrophils is variable although seen in upper 
epidermis commonly. And their role in the pathogenesis of psoriasis is 
unclear. 
Keratinocytes  
Psoriatic keratinocytes express the following, 
 Pro-inflammatory cytokines 
 Chemokines 
 Growth factors 
 Inflammatory mediators like eicosanoids. 
 Innate immunity mediators like defensins, cathelicidins and S100 
proteins. 
Activation of regenerative maturation in psoriasis have been 
noted. But the mechanism by which this occurs is not known at 
present. 
 
Other cells like fibroblasts and endothelial cells are also involved 
actively in the pathogenic process of psoriasis. 
 Fibroblasts produce many chemotactic factors and help in 
migration of T cells out of psoriatic lesions. They also support 
keratinocytes proliferation in a paracrine manner. 
 Endothelial cells are activated in developing as well as mature 
lesions of skin. Due to increase in blood flow to the lesions, influx 
of leukocytes and serum proteins in psoriatic lesions have been 
increased. 
 
Signalling molecules in psoriasis 
Cytokines and chemokines
 
Cytokines upregulated in psoriasis include TNF-α, IL-2,IL-6,  
IL-8, IL-15, IL-17, IL-18, IL-19, IL-20, IL-22. 
Chemokines include CXCL9 & 10, MIP3α / CCL20,  
I-TAC/CXCL11. 
 IL-1 induces the expression of various adhesion molecules like  
ICAM-1,  and VCAM-1, mononuclear cell chemotaxis and also 
the proliferation  of keratinocytes. 
 IL-2 produced by CD4-T cells is indicative of  T cell activation; 
this cytokine has not been reported in psoriatic skin. 
 IL-6 is produced by keratinocytes, fibroblasts, T cells and 
macrophages. It stimulates keratinocytes proliferation in lesional 
skin. IL-6 protein levels are increased in psoriatic keratinocytes in 
vitro. 
 IL-8 (neutrophil activating factor) is a potent chemo-attractant for 
neutrophils.  IL-8 is produced by keratinocytes, fibroblasts, and 
also by lymphocytes
[15]
. 
 IL-18 and IL-23 stimulate production of  interferon-gamma. 
 IL-23 (subset of Th17) is responsible for chronic inflammation in 
psoriasis. 
 TNF-α  is primarily localized in the dermal dendritic cells. 
Presence of TNF-α inducing agents like transforming growth 
factor-α(TGF-α), endothelial expression of adhesion molecules 
like ICAM-1, VCAM-1 and IL-8are all shown to be increased in 
psoriatic skin. 
Angiogenesis is a characteristic component of psoriatic pathology 
and it  is induced by macrophage-derived TNF-α[16,17]. 
PATHOGENESIS OF PSORIASIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 INF-Gamma is produced only by activated CD4 - T cells. Lesion 
from involved psoriatic skin as well as serum from psoriatic 
patients show elevation in IFN-G. IFN-G induces macrophages to 
release high levels of  inflammatory cytokines like TNF-α . 
Innate immune mediators 
 Innate immune mediators are the antimicrobial peptides, like  
human beta defensin-2 and cathelicidin(LL-37).  
They are increased in psoriasis  in response to proinflammatory 
cytokines e.g,. TNF - α ,IL-1, IFN-G. 
 S100A2, S100A7(psoriasin), and S100A8/A9  are overexpressed 
in psoriatic skin lesions which exert chemotactic and 
antimicrobial activity through sequestration of Zn ions. 
 Complement component C5a, a potent chemoattractant for 
neutrophils that contribute for accumulation of the same in 
stratum corneum of psoriasis. 
 
 
 
 
Eicosanoids  
Role of eicosanoids in psoriasis is still unclear.  
Levels of LTB-4, 12-hydroxyeicosatetraenoic acid and 15-
hydroxyeicosatetraenoic acid are increased in lesional skin. But levels 
PGE and PG–F2α are increased less than two fold. 
 
Growth factors 
Following growth factors are over-expressed in psoriasis 
 Members of Epidermal growth factor (EGF) family like 
tansforming growth factor-α (TGF-α), heparin binding EGF like 
growth factor, amphiregulin (ARE6). 
 Keratinocyte growth factor 
 Vascular endothelial growth factor (VEGF) 
 Nerve growth factor (NGF) 
  
Proteases and integrins 
          Levels of serine proteases and leukocyte-derived elastase are 
increasd in psoriasis and may contribute to stimulation of keratinocyte 
proliferation. 
         Integrinα5  and its ligand fibronectin are increased in the 
epidermis of psoriasis. 
 
Signal transduction 
Multiple signal transduction mechanisms like receptor tyrosine 
kinase, Akt, STAT, mitogen-activated protein and NF-кB pathways are 
all dysregulated in psoriasis. 
This will affect activation of immunocytes, trafficking, and also 
keratinocyte responses of proliferation, differentiation and survival. 
 
 
 
 
Histopathology 
Changes in initial lesions 
 Dermal changes like marked edema and mononuclear cell 
infiltrates in the upper dermis precede epidermal changes. 
 Epidermal changes are mild spongiosis and focal loss of granular 
layer. 
 Dilatation of venules in the upper dermis surrounded by minimal 
inflammatory infiltrates are seen
[18]
. 
Developing lesions 
 There will be compact hyperkeratosis, disappearance of the 
granular layer and slight epidermal hyperplasia in developing 
lesions of psoriatic plaque. 
 The lower half of the epidermis shows mitotic figures in the 
keratinocytes,and leukocytic infiltration in spongiotic foci.  
 Munro micro abscess - Scattered mounds of parakeratosis, within 
orthokeratotic stratum corneum, appear with neutrophils.  
 Spongiform pustules of  kogoj - Neutrophils may accumulate in 
the malpighian layer to form this characteristic histopathological 
feature of psoriasis
[19]
. 
 Regular acanthosis with prominently dilated, tortuous papillary 
Capillaries are seen. 
 
Changes in mature lesions
 
 There is parakeratosis and also focal orthokeratosis with 
formation of Munro microabscess. 
 Spongiform pustules in the Malpighian layer, near absence of 
granular layer. 
 Regular elongation of rete ridges and epidermal thinning in 
suprapapillary area. 
 Clubbing of the rete ridges at their bases, with mononuclear 
leukocyte infiltrates in the lower 1/2 of the epidermis.  
 Dilated and tortuous papillary blood vessels, surrounded by a 
mixed mononuclear and neutrophil infiltrate, and also 
extravasated erythrocytes
[20]
.  
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CLINICAL FEATURES 
The first manifestation of psoriasis may occur at any age. The 
course is unpredictable as the duration of illness varies from a few 
weeks to whole lifetime. 
Chronic  stationary psoriasis (plaque type psoriasis / psoriasis   
vulgaris)
[21-25] 
Chronic plaque psoriasis is the most common form of psoriasis, 
accounting 90% of the patients. The plaques are well defined, reddish 
with silvery white scales, symmetrically distributed, localized to 
extensor surface of the body, like elbows, knee, lower lumbo-sacral 
region, buttocks, along with scalp
[21]
.  
Size of the lesion may vary from pinpoint papules to larger 
plaques. The successive removal of scales usually reveals an underlying 
glossy red membrane with small  bleeding points i.e,. positive for 
Auspitz’s sign. About 25% of the patients will have positive history for 
koebnerization which indicates active state of the disease. The plaque 
may sometimes be encircled by a clear peripheral halo known as 
Woronoff’sring[22]. 
 
CLINICAL VARIANTS 
Guttate  Psoriasis. (Eruptive psoriasis) 
Gutta (latin) – ‘ a drop’ 
This is particularly seen in children and young  adults 
characterized by eruption of small papules over trunk and proximal 
extremities (0.5-1.5 cm in size). This type of psoriasis has the strongest 
association to HLA-Cw6. Streptococcal infection mostly precedes or is 
concomitant with the onset or exacerbation of guttate psoriasis
[23]
. 
Bacterial exotoxins produced by Staph. aureus and streptococci 
can act as super-antigens and promote marked T-cell proliferation. 
Rupioid, elephantine and ostraceous psoriasis 
These terms describe plaques associated with gross 
hyperkeratosis. 
Rupioid psoriasis--  limpet-like, cone-shaped lesions.  
Elephantine psoriasis --   unusual, very persistent, thickly scaling, 
large plaques    present over the back, hips, limbs or elsewhere
[24]
. 
Ostraceous  psoriasis -- a ring-like hyper-keratotic lesion with a 
concave surface, resembling an oyster shell. 
 
‘Unstable’ psoriasis 
This term is employed to define the disease in which activity is 
marked and the course as well as outcome of the disease is 
unpredictable; e.g., a patient with chronic stable course of psoriasis, may 
suddenly become erythrodermic or pustular due to inappropriate 
management.  
Precipitating factors for this condition are sudden withdrawal of 
topical/systemic corticosteroid therapy, hypocalcaemia, acute infection, 
overtreatment with tar/dithranol/UV irradiation, and severe emotional 
stress. 
 
PUSTULAR PSORIASIS 
When plaques of psoriasis is studded with superficial tiny 
pustules, it is called pustular psoriasis. 
  
The classification for pustular psoriasis is as follows. 
1. Localized pustular psoriasis:  
The disease is confined to hands and feet, and has a chronic 
course.  
o Palmo plantar pustulosis 
o Acro dermatitis continua of Hallopeau. 
 
2. Generalized pustular psoriasis: 
In this form, the whole body may get involved. The course may 
be acute/ subacute / even life threatening. 
o Acute(Von Zumbusch) 
o Of pregnancy(Impetigo herpetiformis) 
o Infantile and juvenile 
o Circinate 
o Localized (not hands and feet). 
 
Erythrodermic psoriasis   
Two forms exist. In the first form, chronic lesions may progress 
gradually into an exfoliative phase to involve the whole cutaneous 
surface. There are usually some areas of uninvolved skin. The 
characteristics of psoriasis are retained well, mild treatment is generally 
well –tolerated and this form has a better prognosis. 
The second form is part of the spectrum of ‘unstable’ psoriasis. It 
may occur at any time, presenting suddenly, due to increasing 
intolerance to local applications, UV therapy and of loss of control over 
the disease. It is more frequent in psoriatic arthropathy. Itching is often 
severe in contrast to stable form. 
Classification based on site 
Scalp 
Lesions in the scalp are characterized by very thick plaque 
involving the occiput or diffuse plaque affecting the entire scalp. 
A non-specific reaction pattern known as pityriasis (tinea) 
amiantacea is commonly seen in children. It is characterised clinically 
by asbestos like, firmly adherent scales to scalp. Hair loss is not 
common
[25]
. 
Penis 
In uncircumcised male patients, psoriasis may present as  solitary, 
well defined non-scaly plaque on the glans. In such cases it should be 
differentiated from Erythroplasia of  Queyrat or Zoon’s plasma cell 
balanitis. 
Flexural (inverse) psoriasis 
Psoriasis involve the axilla, submammary folds, groin, vulva, and 
gluteal cleft is more commonly seen in adults. The scales are reduced or 
absent with a glazed hue surface and fissuring.  
It will be particularly difficult to differentiate  from infective 
dermatitis and seborrhoeic dermatitis. 
 
Hands and feet 
It may present as well to ill defined  hyperkeratotic scaly plaques 
involving the palms and soles. Eczema should be considered as a close 
differential diagnosis in particular. 
  
NAIL CHANGES IN PSORIASIS 
Nail changes can be seen in up to 40% of patients in psoriasis
 [26]
. 
Nail involvement may be severe in case where psoriasis has early 
onset and familial. All types of  nail involvement may occur in psoriatic 
arthritis. 
 
Nail segment involved                                          clinical sign 
1. Proximal matrix         =>            pitting, Beau’s line,  
     onychorrehexis 
2. Intermediate matrix    =>  leukonychia 
3. Distal matrix      =>  nail plate thinning, focal  
     onycholysis, erythema of lunula 
4. Nail plate                   =>  crumbling and destruction 
5. Nail bed                     =>  onycholysis, splinter   
     hemorrhages,  Salmon patch 
6. Hyponychium     =>  onycholysis,  subungual   
     hyperkeratosis 
ATYPICAL FORMS 
Linear and zonal lesions 
Linear lesions along with typical psoriatic plaques may present as 
part of koebner phenomenon. True linear psoriasis is extremely rare. 
Zonal lesions representing koebner reaction at a site of herpes 
zoster have been described. 
Seborrheic psoriasis 
Patients present with reddish plaques with greasy scales localised 
to seborrhoeic areas (the scalp, glabella, nasolabial folds, presternal 
areas, and flexures) may be a common clinical finding. In most of the 
situation, differentiating it from seborrhoeic dermatitis will be hard. 
Mucosal  lesions 
Oral mucosae 
 Grey, white or translucent plaques, diffuse reddish areas or 
annular forms and geographic tongue have been described. 
 But true mucosal involvement is rare in psoriasis. 
 
 Geographic  tongue  (Benign migratory glossitis / glossitis 
areata migrans) 
-An idiopathic inflammatory condition characterised by focal loss 
of filiform papillae. 
 -Presents as asymptomatic reddish patches with serpiginous 
borders, resembling a map. 
 -Migratory in nature 
 -Association of geographic tongue with HLA Cw6 have been 
identified.
[28-31]
. 
 
Ocular involvement 
 Blepharitis, xerosis, conjunctivitis, keratitis, symblepheron and 
uveitis have been reported in psoriasis
[32]
. 
 Patients with pustular psoriasis or psoriatic arthritis and who were 
on methotrexate have been shown to have features of uveitis. 
 
 
 
PSORIATIC ARTHRITIS
[33,34]
 
 Psoriatic arthritis is an inflammatory arthritis that is seen in  
5%-10% of patients with psoriasis. 
 It is a sero-negative arthritis. i.e., negative for rheumatoid factor. 
 Associated with HLA –B 27, B-38, A-26. 
 
The Moll and Wright classification
[35]
includes following types 
1. Classic psoriatic arthritis involving the distal inter-phalangeal 
joints. 
2. Oligo-articular arthritis. 
3. Rheumatoid type of psoriatic arthritis (symmetric polyarthritis). 
4. Arthritis mutilans. 
5. Psoriatic spondylitis with or without sacroiliitis 
  
DISEASES ASSOCIATED WITH PSORIASIS 
Following diseases have been reported to have association with 
psoriasis- 
They are  
 Cutaneous disorders-- vitiligo,bullous pemphigoid, atopic 
dermatitis, infections (bacterial, viral, fungal), non-melanoma 
skin cancers
[36,37]
. 
 Systemic disorders-- Crohn’sdisease[38], gout[39], chronic recurrent 
multifocal osteomyelitis
[40]
, SAPHO syndrome (synovitis, acne, 
pustulosis, hyperostosis, osteitis)
[41]
. 
COMPLICATIONS 
 Infections -- folliculitis and furunculosis rarely due to staph. 
aureus
[42]
. 
 Itching  -- more common in unstable form. 
 Erythrodermic psoriasis. 
 Psoriatic arthritis. 
 Nephritis and renal failure – mesangio capillary glomerulo-
nephritis, acute tubular necrosis have been reported
[43,44]
. 
 Hepatic failure --  pustular / erythrodermic psoriasis, or due to 
drugs,  oligaemia, alcoholism. 
 Apical pulmonary fibrosis  --  non articular complication of 
ankylosing spondylitis. 
 Secondary amyloidosis. 
 
DIFFERENTIAL DIAGNOSIS  
1. Psoriasis vulgaris :- 
Most likely-  nummular eczema, cutaneous T-cell lymphoma 
(CTCL), tinea corporis 
To rule out-  Bowens disease, paget’s disease (extra-mammary) 
Consider   -   seborrhoeic dermatitis, pityriasis rubra pilaris 
(PRP), hypertrophic LP, Erythro keratoderma, subacute cutaneous lupus 
erythematosus. 
 
2. Erythrodermic :- 
Most likely  -  eczema, CTCL, PRP. 
 
3. Pustular :- 
Most likely - impetigo, reactive arthritis syndrome, candidiasis. 
Consider-  pemphigus foliaceus, IgA pemphigus, subcorneal 
pustular dermatosis, acute generalised exanthematous pustulosis. 
 
4. Guttate :- 
Most likely - lichen planus, pityriasis rosea, pityriasis lichenoides  
chronica. 
To rule out -  secondary syphilis. 
Consider   -   parapsoriasis (small plaque), drug eruption.  
  
INVESTIGATIONS 
For initiation of treatment, following investigations should be done. 
1. Complete blood count –including  platelet count. 
2. Serum calcium. 
3. Serum uric acid. 
4. Renal function test-  BUN, blood urea, serum creatinine. 
5. Blood sugar level. 
6. Liver function tests-  including liver enzymes and protein levels. 
7. Fasting lipid profile-  Total Cholesterol, Triglycerides, HDL-C, 
LDL-C. 
8. Urine routine  –   Albumin, Sugar and Deposits. 
9. Screening -  for HIV, HEP B & C and mantoux test. 
10. Cardiac evaluation- ECG 
11. Radiological evaluation - Chest X-Ray, X-Ray Joints. 
12. Ultrasonogram-  abdomen. 
13. Urine pregnancy test. 
14. Skin biopsy 
CLINICAL SEVERITY ASSESMENT IN PSORIASIS 
Many tools can be used for the assessment of psoriasis clinically. 
They are as follows 
1. BSA - Body Surface Area. 
2. PASI - Psoriasis Area and Severity Index. 
3. SAPASI - Self Administered Psoriasis Area And Severity 
Index. 
4. NAPASI - Nail Psoriasis Severity Index . 
5. CASPAR - Scoring of psoriatic arthritis . 
Among these, PASI is the most commonly used one. 
BODY SURFACE AREA (BSA) 
It is the simplest scoring system which follows the rule of nine as 
in case of burns. It just reflects surface area of the body involved but not 
the severity of the disease.  
 
 
PSORIASIS AREA AND SEVERITY INDEX (PASI)
[45] 
PASI is a useful tool in monitoring the response of psoriasis to 
any therapeutic regimen. 
Four sites are separately scored. They are head (h), upper limbs 
(u), trunk (t) and lower limbs (l). 
Morphological evaluation done by three parameters namely, 
erythema (E), induration (I) and scaling (S). 
They are graded on a severity scale of 0 to 4. 
0 = nil,  1 = mild,  2 = moderate,  3 = severe,  4 = very severe. 
The addition of these scores for each site is multiplied by the 
grading for area wise percentage involvement of that particular site in 
following manner  
1 = < 10% area involved,  2 = 10% to 29%,  3 = 30% to 49% 
4 = 50% to 69%,  5 = 70% to 89%,  6 = > 90% 
Four body regions represent about 10%, 20%, 30% and  40% of 
the body surface area respectively, they are given corresponding score 
of 0.1, 0.2, 0.3 and 0.4. 
The score vary from 0 to 72 in steps of 0.1. 
The main limitation of this scoring system is inter-observer 
variation. This necessitates scoring by the same evaluator. 
 
 AREA 
(A) 
ERYTHEMA 
(E) 
INDURATION 
(I) 
SCALING 
(S) 
HEAD(h)     
UPPER 
EXTREMITY(u) 
    
TRUNK(t)     
LOWER 
EXTREMITY(l) 
    
TOTAL     
 
   PASI=0.1(Eh+Ih+Sh)Ah+ 0.2(Eu+Iu+Su)Au+0.3(Et+It+St)At+0.4(El+Il+Sl+)Al. 
 
 
Nail Psoriasis Severity Index (NAPASI) 
NAPASI is used to evaluate nail psoriasis. Here the nail is divided 
into 4 quadrants by imaginary horizontal and longitudinal lines and 
assessed in each quadrant for: 
 Psoriasis of nail matrix: pitting, leukonychia, red spots in lunula 
and crumbling of nail plate. 
 Psoriasis of nail bed: oil drop sign, onycholysis, splinter 
hemorrhage, sub-ungual hyperkeratosis, nail discoloration. 
NAPASI Scoring  
Score Lesions 
0 If  findings are absent. 
1 If  present in 1 quadrant of nail. 
2 If  present in 2 quadrants of nail. 
3 If  present in 3 quadrants of nail. 
4 If  present in 4 quadrants of nail. 
 
Nail score is obtained by the summation of nail matrix and nail 
bed scores (0-4 each) NAPSI is obtained by adding the total score of all 
involved nails. 
 
CASPAR (Classification Criteria for Psoriatic Arthritis) 
 Current psoriasis (assigned a score of 2) 
 A history of psoriasis (in the absence of current psoriasis; 
assigned a score of 1) 
 A family history of psoriasis (in the absence of current 
psoriasis and history of psoriasis; assigned a score of 1) 
 Dactylitis (assigned a score of 1) 
 Juxta-articular new bone formation (assigned a score of 1) 
 RF negativity (assigned a score of 1) 
 Nail dystrophy (assigned a score of 1) 
 
 
 
TREATMENT 
Following treatment options available, 
1. TOPICAL : Emollients, Keratolytics, Tar, Anthralin, Vitamin D 
analogues, Vitamin A analogues (retinoids), Calcineurin inhibitor, 
Corticosteroids. 
2. PHOTOTHERAPY : PUVA, NB-UVB. 
3. SYSTEMIC: Methotrexate, Cyclosporine A, Retinoids, 
Hydroxyurea, Systemic steroids, Fumaric acid esters, 
Mycophenolate mofetil, Biological agents. 
4. MISCELLANEOUS:  6-thioguanine, Azathioprine, Sulfasalazine, 
protein kinase C inhibitors, Tacrolimus, Pimecrolimus, 
Zidovudine, Liarozole, Somatostatin, Photodynamic therapy, 
Lasers-excimer (308nm). 
 
 
 
 
ALGORITHM FOR TREATMENT OF PSORIASIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Psoriasis 
Erythrodermic/pustular 
psoriasis 
 Acitretin 
 PUVA, NB-UVB 
 Methtrexate 
 Cyclosporine A 
 Systemic 
steroids 
 biologicals 
Chronic plaque 
psoriasis 
Guttate psoriasis 
 No treatment 
 NB-UVB 
 BB-UVB 
 TOPICAL  
- VIT-D 
ANALOGUES 
- STEROIDS 
MILD <10% BSA MODERATE >10% BSA SEVERE >30% BSA 
SYSTEMIC 
TREATMENT 
1
st
 line 
 Methotrexate 
 Acitretin 
 Biologicals 
- Alefacept 
- Afalizumab 
- Remicade 
- Adalimumab 
2
nd
 line 
 Fumarate ester 
 Cyclosporin A 
 Others 
-azathioprine 
-sulfasalazine 
 
DAY TREATMENT 
CENTRE 
Modified 
Goeckerman 
Phototherapy 
1
st
 line 
- NB-UVB 
- BB-UVB 
2
nd 
line 
- PUVA 
- EXCIMER 
- CLIMATOT
HERAPY 
Topical treatment 
1
st
 line 
- Emollients 
- Glucocoticids 
- vitD3 analogs 
2
nd
 line 
- Dithranol 
- Tazarotene 
- Tar  
METHOTREXATE (MTX) 
Methotrexate, a potent folic acid antagonist, acts by inhibiting the 
enzyme dihydrofolate  reductase. Initially approved for the treatment of 
psoriasis by USFDA and now used widely in various dermatological 
condition
[46]
. 
 
MECHANISM OF ACTION 
MTX is a folic acid analog which acts as a competitive inhibitor 
for folate receptors. It enters cells either through an active transport 
mechanism or by facilitated diffusion. Active metabolites of MTX 
(polyglutamated forms) are potent inhibitors of DHFR and also play a 
key role in toxicity
[47]
. 
 
DNA SYNTHESIS EFFECTS 
Methotrexate causes inhibition of cell division, which is specific 
for S-phase of the normal cell cycle. i.e., DNA synthesis. 
Methotrexate competitively and reversibly inhibits dihydrofolate 
reductase enzyme with an affinity greater than that of folic acid. This 
prevents the conversion of dihydrofolate to tetrahydrofolate. 
Tetrahydrofolate [THF] is a cofactor in production of 1-carbon units, 
therefore needed for DNA and RNA synthesis. Other than DHFR, 
thymidylate synthase is also inhibited by MTX. 
MECHANISM OF ACTION- METHOTREXATE  
 
 
 
 
 
EFFECTS ON T & B CELLS 
Methotrexate not only affects the lymphocytes proliferation, but 
also inhibits migration of activated T cells. It depresses cutaneous 
lymphocyte associated antigen positive T cells and E-selectin of 
endothelial cells.  
Though MTX can suppress both primary and secondary antibody 
responses, no significant effect on delayed type hypersensitivity has 
been noted. 
 
ANTI-INFLAMMATORY EFFECTS 
Anti-inflammatory effect of methotrexate is because of its inhibitory 
action on folate dependent enzyme i.e,.5-aminoimidazole carboxamide 
ribonucleoside transformylase (AICART). 
This will lead to accumulation of AICAR and release of 
adenosine. With potent anti-inflammatory effects, adenosine inhibits 
secretion of pro-inflammatory cytokines like IL-6,-8, TNF-α, INF-γ and 
also retards function of polymorphonuclear lymphocytes. Modulation of 
intercellular adhesion molecule-1 (ICAM-1) has also been noted. 
 
PHARMACOKINETICS 
Methotrexate can be given orally, subcutaneously, 
intramuscularly and also intravenously. It is rapidly absorbed orally, 
although absorption may be variable with higher doses. Plasma peak 
level reaches slowly after an hour of ingestion. In some cases intrathecal 
injection of drug is needed as its penetration of blood brain barrier is 
poor. 
Once absorbed, methotrexate undergoes a triphasic reduction in 
plasma. In first phase (3/4
th
of an hour),distribution of the drug occurs 
throughout the body. 
In 2
nd
 phase, plasma level is reduced over 2-4 hours due to 
excretion of the drug via kidney. Methotrexate being a weak organic 
acid, its predominant mode of excretion is through the kidneys. 
During 3
rd 
phase, methotrexate is released slowly from the tissues 
as it is primarily bound to dihidrofolate reductase. The terminal half-life 
therefore varies between 10-27 hours. 
Methotrexate is primarily available as 2.5mg tablet but recently  
5, 7.5, 10 and 15 mg tablets are also available in the market. Injectable 
form is available as solution for intravenous, intramuscular, intrathecal, 
and subcutaneous administration (2-ml vials with 2.5 to 25mg/ml). 
INDICATIONS
 [48] 
FDA-approved dermatologic indications 
 Psoriasis, Sezary syndrome 
Off - label dermatological uses 
 Proliferative dermatoses-Reiter’s disease, Pityriasis lichenoides et 
varioliformis acuta, Pityriasis rubra pilaris.  
 Immunobullous diseases-Pemphigus vulgaris, cicatrical 
pemphigoid, Epidermolysis bullosa aquisita, Bullous pemphigoid. 
 Vasculitis and neutrophilicdermatoses –Pyoderma gangrenosum 
,Leucocytoclastic vasculitis, Cutaneous polyarteritis nodosa, Behcets 
disease, Kawasaki disease. 
 Connective tissue disorders - Morphea / localized scleroderma, 
subacute cutaneous lupus erythematosus, systemic lupus 
erythematosus, Dermatomyositis, Systemic scleroderma. 
 Dermatitis- Atopic dermatitis 
 Other dermatoses 
Kertoacanthoma, Sarcoidosis, Keloids, mycosis fungoides, 
Lymphomatoid papulosis, Cutaneous crohn’s disease, Chronic 
idiopathic urticaria. 
Contraindications 
Absolute  
Pregnancy and lactation 
Relative  
Unreliable patients, renal and hepatic diseases metabolic diseases 
like diabetes mellitus, severe hematological abnormalities, men or 
women contemplating conception, any active infections (eg., TB), 
immunodeficiency syndromes. 
Adverse effects
 
 Hepatotoxicity – the risk of methotrexate induced cirrhosis 
varies from 0 – 25% in various reports. The risk of liver 
damage can be reduced when the cumulative dose is below 
1.5g.Patients with cumulative dose of 4.0 g or above are 
particularly at risk for developing cirrhosis and liver fibrosis. 
Intake of alcohol and other hepatotoxic drugs will further 
aggravate the toxicity. 
 Pulmonary toxicity – acute pneumonitis, a rare life 
threatening complication have been reported in patients who 
received small doses of MTX. Pulmonary fibrosis develops 
more gradually in long term patients. 
 Haematological abnormalities – methotrexate can cause 
pancytopenia which can endanger patient’s life. Routine folic 
acid supplementation will reduce the risk of pancytopenia.  
Concurrent use of sulphonamides and NSAIDs will further 
aggravate the risk of toxicity. Leucovorin (folinic acid) should 
be promptly used in case of acute toxicity. 
 Malignancy induction – use of methotrexate in collagen 
vascular diseases is associated with lymphoma but it is rarely 
reported in patients with psoriasis. 
 
 
 
  Gastrointestinal effects  
Most commonly reported adverse effects are nausea and anorexia 
whereas, diarrhoea and ulcerative stomatitis are less frequently 
noted. 
 Reproductive effects 
Methotrexate is a potent abortifacient and teratogen, but shows 
very less mutagenic and carcinogenic potential when compared 
with alkylating agents.  Women of child bearing age who take 
methotrexate must use reliable birth control measures. It can also 
cause reversible oligospermia in men. 
 Renal effects 
 High dose (i.e., 50-250mg/m
2
 intravenously) methotrexate 
therapy may lead to renal toxicity due to precipitation of 
methotrexate in renal tubules. 
 
 
 
 Other adverse effects   
Headache, fatigue, alopecia, phototoxicity,  papular eruption, 
acral erythema, toxic epidermal necrosis, cutaneous ulceration, 
vasculitis, osteopathy and  rarely stress fractures. 
MONITORING 
Before starting the drug careful history taking and physical 
examination should be done. 
LABORATORY 
 Complete blood count including platelet count. 
 Liver function test. 
  Renal function test.(including BUN) 
 Screening for HIV, hepatitis B&C. 
 Urine pregnancy test. 
 Chest x ray and mantoux test. 
  
Guidelines to follow up are 
 CBC including platelet count and LFT- 5-6 days after test dose. 
Every 1-2 wks for 2-4 wks. Gradually decrease to every  
3-4 months. 
 Renal function test- once or twice yearly. 
 Liver biopsy- should be done for low risk patients after every  
1.5-2.0 g total dose. For high risk patients every 1.0 g of total 
dose. 
 
  
AZATHIOPRINE 
Azathioprine, a purine analog, was introduced in 1961 for renal 
transplantation as an immunosuppressant. 
In dermatology it is used as a steroid sparing agent, therefore 
allowing to decrease the dose of systemic steroids or can be used as 
monotherapy. It is less toxic than its parent component 6-
mercaptopurine (6-MP)
[49]
.
 
MECHANISM OF ACTION 
Conversion of azathioprine to 6-MP initially, followed by 
anabolization to its active form 6-thioguanine (6-TG), by the enzyme 
hypoxanthine guanine phosphoribosyl transferase (HGPRT) occurs 
following absorption. 6-TG is similar structurally to purine adenine and 
guanine, so that is incorporated into DNA and RNA inhibiting purine 
metabolism and cell division
[50]
. 
Both T and B cell mediated functions are depressed. Diminished 
B cell function results in decreased antibody production, which is of 
central importance in its usage in immunobullous disorders
[51]
. 
 
MECHANISM OF ACTION- AZATHIOPRINE 
 
 
 
 
 
Number and functioning of Langerhans cells and other antigen 
presenting cells in the skin are decreased. This will further enhance the 
immuno-suppressive effects of the drug. 
Other than the active component (6-TG) of the drug, two inactive 
metabolites are produced by the enzymes Xanthine oxidase and 
thiopurine methyl transferase (TPMT)
[52]
. 
 
PHARMACOKINETICS 
Azathioprine is well absorbed orally (88%). It reaches peak 
plasma levels in less than 2 hrs with half- life around 5 hrs. 
The drug is completely metabolized and its active metabolite  
6-TG accumulates in tissues to provide maximal clinical benefits around 
8-12 wks. 
It can easily cross the placenta, but not the blood brain barrier. 
Dosage is 1-3 mg/kg/day. Available in 25,50,75,100-mg tablets. 
An injectable formulation is also available (100 mg vial). 
 
 
INDICATION 
FDA-APPROVED 
 Organ transplantation. 
 Severe rheumatoid arthritis 
(none specific to dermatology) 
 
OFF-LABEL DERMATOLOGIC USE 
 Immuno-bullous dermatoses -  Bullous pemphigoid, pemphigus 
vulgaris, cicatrical pemphigoid. 
 Neutrophilic dermatoses - Behcet’s syndrome, pyoderma 
gangrenosum. 
 Connective tissue disorders - SLE, DLE, relapsing 
polychondritis, dermatomyositis. 
 Dermatitis and papulosqaumous diseases- contact dermatitis. 
Atopic dermatitis, psoriasis, lichen planus. 
 Vasculitis – polyarteritis nodosa, wegener’s granulomatosis. 
 Photodermatoses - actinic dermatitis, PLE, persistent light 
reaction. 
 Others - erythema multiforme, sarcoidosis, chronic GVHD. 
 
CONTRAINDICATIONS 
Absolute- pregnancy, hypersensitivity to drug, any active infections. 
Relative- use of allopurinol, prior use of alkylating agent. 
 
ADVERSE REACTIONS 
 Myelosuppression - neutropenia, agranulopenia and 
pancytopenia. 
 Infections - herpes simplex, HPV, scabies. 
 GIT - gastritis, pancreatitis. 
 Hepatic - transient elevation in enzymes level, rarely 
hepatotoxicity. 
 Teratogenicity - congenital malformations like polydactyly, 
myelo-meningocele, talipus equino varus. 
 Malignancies - lymphoma and cutaneous SCC. 
 Hypersensitivity syndrome - cutaneous eruptions varies 
from morbilliform to erythema nodosum like. 
 
MONITORING 
Before starting the drug, complete clinical evaluation to focus on 
skin and lymphoreticular system should be done. 
History of use of allopurinol or any alkylating agents has to be 
elicited. 
LABORATORY 
 Urine pregnancy test. 
 Complete blood count including platelet count. 
 Liver and renal function tests. 
 Mantoux test, chest x ray. 
 Urine analysis. 
 Screening for HIV. 
SPECIAL TEST 
Dose modification should be done according to TPMT assay
[53]
, 
before initiation of AZT, 
 If TPMT level < 5.0 U = no treatment with azathioprine. 
 TPMT > 5.0 U but < 13.7 U = 0.5 mg/kg maximum daily dose. 
 TPMT > 13.7 U but < 19.0 U = 1.5 mg/kg maximum daily dose. 
 TPMT > 19.0 U = 2.5 mg/kg maximum daily dose. 
No need to repeat the TPMT assay following baseline 
determination closely. 
 
Guidelines to follow up are 
 Complete blood count including platelet count. 
 Liver function test including AST & ALT. 
Tests should be done biweekly for the first 2 months, every  
2-3 months thereafter
[54]
. 
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AIMS AND OBJECTIVES OF THE STUDY 
 
1. To compare the EFFICACY, SAFETY and TOLERABILITY  
of  ORAL  METHOTREXATE 15mg/week Versus  ORAL 
AZATHIOPRINE 50mg/day in chronic plaque psoriasis. 
 
2. To look for adverse effects during and after the treatment 
 
 
 
 
 
 
  
 
 
 
METHODS AND 
MATERIALS 
 
 
 
 
 
METHODS AND MATERIALS 
PLACE OF STUDY: GOVT. STANLEY MEDICAL 
COLLEGE & HOSPITAL, CHENNAI. 
TYPE OF STUDY :  RANDOMISED, PROSPECTIVE, OPEN 
LABEL, PARALLEL GROUP COMPARATIVE STUDY. 
TIME DURATION : One year.(June 2013 to May 2014) 
SAMPLE SIZE :  2 groups, each containing  20 patients. 
 
STUDY PROCEDURE 
This study was conducted in accordance with the ethical 
committee approval obtained on June 2013 (Annexure 3) 
A brief and relevant medical history with physical examination 
will be taken at screening visit to ensure all the relevant eligibility 
criteria are met.(Annexure 1). 
Informed and written consent was obtained(Annexure 2). 
After successful screening, patient would be randomised to one of 
the two treatment groups as follows, 
GROUP A(n=20) : Patients who fulfil inclusion criteria and 
willing to take part in trial and sign consent letter would be included in 
the study. They would be administered T.METHOTREXATE 
15mg/week for 12 weeks. Efficacy will be assessed by monitoring PASI 
score every week. Safety and tolerability monitored by clinical 
examination with complete haemogram weekly and liver function test 
biweekly. 
GROUP B(n=20) :  Patients who fulfil inclusion criteria and 
willing to take part in trial and sign consent letter would be included in 
the study. They would be administered T.AZATHIOPRINE50mg/day 
for 12 weeks. Efficacy will be assessed by monitoring PASI score every 
week. Safety and tolerability monitored by complete haemogram  and 
liver function tests  biweekly. 
In both the groups, adjuvant treatment with topical emollients like 
liquid paraffin was allowed. 
Endpoints and Assessments 
The primary endpoint was achieving PASI 75 at week 12. Patients 
in both the groups who had achieved PASI 75 and PASI 50 at week 12 
were then followed  up for a period of 12 weeks, to look for any adverse 
effects and decrease in efficacy. 
Thus, all patients were assessed at screening, at baseline, and 
every weeks thereafter. Safety of both the drug regimens was evaluated 
by the incidence of adverse effects (CTC version 2.0)
[55]
and changes in 
laboratory parameters. 
Inclusion criteria:  
1) Male       Chronic plaque type- Psoriasis 
2) Female    
3) Age >18 years  
4) PASI >10  
5) Investigations within normal limits. 
6) Patients willing for trial and  follow up. 
 
 
 
 Exclusion criteria: 
1) Pregnant and lactating woman. 
2) Patients who received oral or parenteral treatment for Psoriasis 
vulgaris during the 4 weeks before trial or topical treatment 
during the week before trial. 
3) Other clinical type of psoriasis like erythroderma, pustular 
psoriasis that would interfere with study evaluation. 
4) Active Bacterial or viral skin infections. 
5) Patients on any other immunosuppressant drugs. 
6) HIV Patients. 
7) H/o active TB / old case TB. 
8) H/o Cardiac disease. 
9) H/o liver disease and 
10)H/o renal disorder. 
 
Investigations: 
 Complete haemogram including platelet count. 
 Liver function test. 
 Renal function test. 
 Blood glucose level. 
 Serum calcium and uric acid. 
 HIV and VDRL screening 
 Hepatitis  B & C 
 Mantoux test 
 Chest x-ray, ECG 
 Ultrasound Abdomen and pelvis 
 ENT & dental opinion to r/o focal sepsis 
 Skin biopsy. 
 
 
  
 
 
 
OBSERVATION AND 
RESULTS 
 
 
 
OBSERVATION AND RESULTS 
This study was started in June 2013 and completed in May 2014 
when the last patient completed his follow up. A total of 40 patients 
were enrolled in the study who were randomised to either of the two 
treatment groups. All the 40 patients in both groups received the specific 
dose of  medication and completed  24 weeks of the study period. 
Patient demographics and baseline disease characteristics were 
generally well balanced across both the treatment groups. Youngest age 
of the patient in this study was 23 years and oldest was 64 years. The 
mean age was 42 years. The highest score of PASI was 21.8 and lowest 
was 12.3.Mean PASI score at baseline was 16.1.The mean duration of 
Psoriasis at baseline was 5 years. 
In the Methotrexate and Azathioprine groups, respectively, 
17(85%) and 16(80%) had received prior systemic therapy or  
phototherapy.  
13(65%) patients in the Methotrexate group and 14 patients in the 
Azathioprine group (70%) had nail involvement in the form of pitting, 
nail dystrophy, beau’s lines and / or subungual hyperkeratosis. 
 
Total number of patients in the study:  40 
Study population 
This study included 40 patients ; 33 male and 7 female patients. 
Youngest patient was 23 years of age and oldest was 64 years of 
age. All the patients fulfilled the inclusion and exclusion criteria. 
Table 1 – Age wise distribution of study population 
          Age group (years)           No. of patients  
                 20 – 40                  18 
                 41 – 60                  19 
                 61 – 80                    3 
 
 
 
 
 
The collected data was analysed and data descriptive statistics 
frequency analysis, mean, S.D, percentage analysis were used to 
describe it. Independent  t-test was used to find the difference between 
bivariate samples. Chi-square test was used for categorical values. 
Probability value (P= .05) is considered as significant in all above 
statistical stools. 
Chart 1 : Mean Age of study population 
 
 
The mean age of study population was 42. The mean age in 
methotrexate group was 44 and azathioprine group was 41. 
 
 
Table 2: Sex wise distribution of study group 
      Drug      Male      Female   Total 
  Methotrexate        16           4     20 
  Azathioprine        17           3     20 
 
Chart 2: Sex wise distribution of study cases 
 
 
 
 Chart 3 : Mean duration of illness in both groups 
 
Mean duration of the disease in both groups were 5 years. 
 
  
EFFICACY 
At week 12 PASI 75 response was achieved by 14 patients in 
Methotrexate group and 5 patients in Azathioprine group ( 70% vs 25%;  
p=0.036 ). Similarly PASI 50 response was achieved by 6 patients in 
Methotrexate group and 13 patients in Azathioprine ( 30% vs 65% ).  
2 patients in Azathioprine group achieved PASI 25 at week 12 (10% ). 
In the Methotrexate group mean PASI decreased from 16.2 at 
baseline to 4.2 at 12 week (74%). And in Azathioprine group it was 
from 15.3 to 5.6 (62.1%) 
The mean duration of remission in Methotrexate group was 2 
months and in Azathioprine group it was 1 month. 
 
 
 
 
 
 
Table 3 : Week wise reduction in Mean PASI score 
        Duration  Methotrexate Azathioprine 
Baseline 16.2 15.3 
4 weeks 12.6 12.9 
8 weeks 7.7 8.5 
12 weeks 4.2 5.6 
 
This table shows weekly reduction in Mean PASI score from the 
baseline. In the Methotrexate group mean PASI decreased from 16.2 at 
baseline to 4.2 at 12 weeks (74%). And in Azathioprine group it was 
from 15.3 to 5.6 (62.1%) 
 
 
 
 
 
                    Chart 4 : Week wise reduction in PASI 
 
 
 
  
Table 4 : Week wise reduction in PASI score – Methotrexate 
   Week       25%        50%       75% 
   Week 4       6         0        0 
   Week 8       4         16        0 
   Week 12       0          6        14 
 
Table 5 : Week wise reduction in PASI score – Azathioprine 
Week 25% 50% 75% 
    Week 4       7         0       0 
    Week 8       14         6       0 
    Week 12       0         15       5 
 
 
 
                 Chart 5 : Percentage reduction in PASI – 4th week 
 
 
 
 
 
 
 
Chart 6 : Percentage reduction in PASI – 8th week 
 
 
 
 
 
 
 
Chart 7 : Percentage reduction in PASI – 12th week 
 
 
 
 
 
 
 
WEEK 12 Chi-Square test 
  
Value 
 
df 
Asymp.sig.                                                                                                        
(2-sided) 
Pearson Chi-Square 
Likelihood Ratio 
Linear-by-Linear 
Association 
N of valid cases 
    6.623
a 
    6.301 
    6.193 
 
        19 
       2 
       2 
       1 
.036 
.043 
.013 
 
a. 5 cells (83.3%) have expected count less than 5. The minimum 
expected count is .26. 
 
 
 
 
 
Table 6 : Response to treatment in both groups 
 
Result 
% PASI 
reduction at 
week 12 
 
Methotrexate 
 
Azathioprine 
Excellent >75%   14 (70%) 5  (25%) 
Good 51-75% 6 (30%)    13 (65%) 
Moderate 25-50%    0      2 (10%)  
Poor <25%    0     0 
 
 
 
 
 
 
 
                   Chart 8 :  Nail involvement in both groups 
 
 
      13 patients in Methotrexate groups and 14 patients in 
Azathioprine group were shown nail changes. 
 
 
 
SAFETY AND TOLERABILITY 
Overall 20% in the methotrexate group experienced adverse 
effects, but only 5% in Azathioprine group experienced it during the 
study period. (p=0.151) 
           Of the four patients in the Methotrexate group who developed 
adverse effects, two had gastritis, one had headache and one had 
diarrhoea. Patients who had gastrointestinal side effects, improved with 
proton pump inhibitors and folic acid. One who had headache tolerated 
the medication during subsequent weeks.   
          In Azathioprine group, one patient developed gastritis, but 
improved with proton pump inhibitors.  
         No significant haematological, dermatological, systemic adverse 
effects were observed in either of both groups during and follow up 
period of the study. 
        Likewise no specific adverse effects leading to withdrawal 
occurred in either of both the study groups. In general, both the drugs 
were well tolerated. 
 
ADVERSE EFFECTS –CROSSTABULATION 
 MA  
Total 
MEYHOTREXATE AZATHIOPRINE 
AE      + Count 
            % within MA 
             4 
             20% 
           1 
           5% 
        5 
      12.5% 
           Nil     Count 
            % within MA 
            16 
            80% 
          19 
          95% 
      35 
      87.5% 
Total     Count 
            % within MA 
            20 
           100% 
          20 
         100% 
      40 
      100% 
 
 
 
 
 
 
 
CHI-SQUARE TEST 
 Value Df Asymp. 
sig 
(2-sided) 
Exact.sig 
(2-sided) 
Exact.sig  
(1-sided) 
Pearson Chi-Square 2.057
a
 1   .151   
Continuity correction
b
 .914
 
1   .339   
Likelihood ratio 2.185 1   .139   
Fisher’s Exact Test    .342 .171 
No of valid cases 40     
 
2 cells (50.0%) have expected count less than 5. The minimum 
expected count is 2.50. 
 
 
 
 
                    Chart9 : Adverse effects in both groups 
 
 
Overall 20% in the methotrexate group experienced adverse 
effects, but only 5% in Azathioprine group experienced it during the 
study period. (p=0.151) 
 
 
              Chart 10 : Duration of remission in both groups 
 
 
The mean duration of remission in Methotrexate group was 2 
months whereas in Azathioprine group it was 1 month. (p= 0.001) 
 
 
T-test 
Group statistics 
   MA         N      Mean Standard 
deviation 
Standard 
error 
Remission 
Methotrexate 
Azathioprine 
     20 
     20 
   1.900 
   1.325 
   .6407 
   .3726 
    .1433 
    .0833 
 
Independent sample test 
 
 
Remission 
Levene’s 
test for 
equality 
of 
variance 
 
 
 
 
T-test for equality Means 
F Sig. T Df Mean 
difference 
Sig 
(2-
tailed) 
 
Std. 
err.diff 
95%confidence 
interval 
lower Upper 
Equal 
variances 
assumed 
4.164 .048 3.469 38 .5750 .01 .1657 .2395 .9105 
Equal 
variances 
not 
assumed 
  3.469 30.531 .5750 .02 .1657 .2368 .9132 
 
  
 
TREATMENT RESPONSE 
METHOTREXATE 
(GROUP A) 
 
 
 
 
 
BEFORE TREATMENT 
PATIENT 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
AFTER TREATMENT 
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AZATHOPRINE 
 (GROUP B) 
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BEFORE TREATMENT 
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DISCUSSION 
 
 
 
 
 
DISCUSSION 
Psoriasis is a multisystem disorder with varying prevalence 
among different races of population in the world. Although various 
treatment modalities are available, no drug is curative for psoriasis. And 
the search for the safest, most efficacious and least toxic drug is still 
going on to provide a long-lasting relief from the disease.  
Methotrexate 
Methotrexate is not only efficacious in plaque type psoriasis, but 
also in psoriatic arthropathy, pustular psoriasis and  psoriatic 
erythroderma. It is usually used in chronic plaque psoriasis where 
conventional treatment like topicals and phototherapy (including UVB 
and PUVA) were failed. 
       In our study the mean decrease in PASI score at week 12 in those 
who received  T.Methotrexate 15mg/week was 74% (cumulative dose of 
180 mg).  At week 12, PASI 75 was achieved by 70% of the patients 
and  rest of the 30% of  the patients had achieved a minimum of PASI 
50. The average duration of remission in this group was two months. 
Four out of twenty patients had developed adverse events. 
 
This data correlates with various studies conducted namely, 
1. A study by Heydendael et al[56], comparing the efficacy of 
Methotrexate and Cyclosporine in 85 patients with moderate to 
severe plaque psoriasis, showed that  methotrexate administered 
at a dosage of at least 15 mg weekly for 16 weeks effectively 
cleared psoriasis. In this study, mean reduction in PASI from 
baseline after 16 weeks was 64%. PASI 75 was achieved by 60% 
of the patients at 16 weeks and the average period of remission 
was 6 weeks. 
2. Sandhu et al[57]conducted one study, comparing Methotrexate and 
Cyclosporine in 30 consecutive patients with severe psoriasis, 
showed a more rapid clinical response, with a 69.4% 
improvement in mean PASI after one month of methotrexate 
therapy (mean dose of 27.7 mg weekly). 
 
  
AZATHIOPRINE 
Azathioprine is effectively used in the field of dermatology. There 
is a vast clinical experience of its use in the treatment of immuno-
bullous disorders and as an adjuvant therapy to steroids.  
But its usage in the treatment of psoriasis is not common. It has 
shown a relatively good safety profile as an immuno suppressive agent 
but there were only few studies available to know about its efficacy and 
safety in the treatment of psoriasis. 
In our study, Azathioprine was used at a lower dose and the mean 
decrease in PASI score at week 12 in those who received 
T.Azathioprine 50mg/day was 62.1%. At week 12, PASI 75 was 
achieved by 25% of the patients and 65% of the patients had achieved of 
PASI 50.  
10% of patients achieved PASI 25 at week 12.The average 
duration of remission in this group was one month. Only one of twenty 
patients in this group had developed adverse effect. 
  
This data correlates with following studies conducted namely, 
1. In a study by Du vivier et al[58], 29 patients were given high dose 
of Azathioprine  upto 300 mg for 6 months. 66% of the patients 
had achieved PASI 75. In their study, leukopenia and deranged 
liver function tests necessitated discontinuation of treatment in 3 
patients. But our study was of shorter duration and we 
administered lower dosages. 
2. Another study by Greeves and Dawber[59], shown improvement of 
only 25% in PASI clearance in half of the patients. But their study 
lasted  only for 6 weeks, as azathioprine need about 6 to 8 weeks 
for its maximal anti-proliferative effects on skin lesions. 
There is only one published study comparing Methotrexate and 
Azathioprine in chronic plaque psoriasis.  
In a study by Tariq malik and Amerejaz
 [60]
, which included 50 
patients for a period of  8 weeks. In this study, group A received tablet 
methotrexate 10 mg weekly and group B received tablet azathioprine   
50 mg thrice daily. PASI score was assessed at the start and end of the 
treatment. Patients were followed up for 4 weeks after the study. 
 
PASI 75 was seen in 73% of patients in Methotrexate  group 
while in Azathioprine  group it was 27% patients at 8
th
 week. And PASI 
50 was achieved by 45% and 55% by Methotrexate and Azathioprine 
groups respectively. There were 5 drops out due to thrombocytopenia 
and deranged liver function tests. 
The data of this study correlated with our study, particularly in 
achieving PASI 75 at week 12 by both the groups. And there was no 
drop out in our study. 
         In our study Methotrexate was more efficacious than 
Azathioprine in achieving PASI 75 at week 12 (70% vs 25%). Both the 
drugs were safer and tolerable while remission period in the 
Methotrexate group was longer than Azathioprine group. 
 
  
  
 
 
 
CONCLUSION 
 
 
 
 
 
CONCLUSION 
 Methotrexate is more effective than Azathioprine  in the treatment 
of chronic plaque psoriasis. 
 Methotrexate had proven its efficacy in the management of 
psoriasis with many established trials and studies for more than 
50 years. 
 There were only few clinical studies of Azathioprine in the 
management of psoriasis. 
 Even after introduction of newer agents like biologics, 
Methotrexate still remains the first line drug in the treatment of 
moderate to severe psoriasis. 
 Advantage of both drugs were  
- Lower cost 
- Easy availability. 
- Choice of oral administration. 
- Easy monitoring with routine blood tests. 
- Better patient compliance can be achieved. 
 Main disadvantages of both the drugs were concurrence of 
systemic diseases such as severe infections like tuberculosis, 
renal disease, liver disorder and congestive cardiac failure. So 
these complications will preclude the use of the agents. 
 Adverse effects associated with azathioprine are causally 
related, usually mild in severity and may resolve without a 
reduction in dosage. 
 Azathioprine can be considered as an alternative treatment 
option in selected patients of chronic recalcitrant psoriasis 
when methotrexate can not be used. 
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ANNEXURES 
 
 
 
 
 
 
 
ANNEXURE I 
GOVERNMENT STANLEY MEDICAL COLLEGE HOSPITAL 
                   DEPARTMENT OF DERMATOLOGY 
                                      PROFORMA 
NAME :                                                                  AGE : 
SEX : 
OCCUPATION :                                                    INCOME : 
CHIEF COMPLAINTS : 
H/O PRESENT ILLNESS : 
Onset  
Duration  
H/O drug intake/ native treatment  
H/O systemic symptoms 
H/O active skin infections 
PAST HISTORY 
H/O Pulmonary tuberculosis/ diabetes/ hypertension/ bronchial asthma 
H/O major medical/ surgical illness 
FAMILY HISTORY : 
H/O similar complaints in family members 
 
PERSONAL HISTORY : 
Diet : 
Sleep : 
Appetite : 
Bowel and bladder habits : 
Habits : smoking/ alcoholism 
Menstrual history (in females) : menarche /menopause, cycles, flow 
Obstetric history (in females) : pregnancy / abortions, lactation 
Treatment history  
H/O drug allergy 
H/O prior systemic / phototherapy 
GENERAL EXAMINATION : 
Consciousness, orientation 
Built and nourishment 
Febrile / afebrile 
Pallor / cyanosis / clubbing / icterus / lymphadenopathy / pedal edema 
Pulse rate :                                                Blood pressure : 
Temperature :                                           Respiratory rate : 
 
 
SYSTEMIC EXAMINATION : 
Cardiovascular system : 
Respiratory system : 
Abdomen : 
Central nervous system : 
LOCAL EXAMINATION : 
Skin and mucosa : 
Scalp and hair : 
Palms and soles : 
Nails : 
PASI score : 
Diagnosis : 
INVESTIGATIONS : 
CBC :Hb%          Blood glucose                     ECG 
TC             LFTS.     calcium, uric acid 
           DC            CXR &Mx test  Renal function test 
ESR             HIV                                   VDRL     
 
 
 
                                   ANNEXURE II 
CONSENT FORM 
Mr / Mrs / Miss : 
Age : 
Address with phone : 
I undersigned Mr / Mrs / Miss ------------------------------------------
have  been explained regarding above said study /procedure in my 
regional language. I am fully aware of the possible side effects and risks 
involved in this study / procedure. I am also aware of that this procedure 
may not always be successful and no guarantee can be made for 
successful outcome of the procedure.  
I have been informed that this study / procedure will be performed 
by Dr.V.SRIDHAR. 
I have also been explained that during this procedure if any 
complication arises, I may be given any emergency treatment best 
suitable without asking my prior permission. 
I further state that I have carefully read and understood all the 
information provided in this form and with full conscious mind I hereby 
give my consent for the said study / procedure with its risk involved. 
 
Signature of the patient / right thumb impression : 
Signature of the Witness : 
Date : 
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METHOTREXATE  (GROUP A) 
S.No 
 
 
Age Sex Duration 
of 
illness 
(yrs) 
P   A   S   I     S   C   O   R   E 
 
Remission 
in months 
Adverse 
effects 
Nail 
involve 
ment W1 W2 W3 W4 W5 W6 W7 W8 W9 W10 W11 W12 
1 23 M 2 16.9 16.9 14.4 14.4 12.7 10.3 8.8 6.9 5.2 5.2 4.2 4.2 2 Nil Nil 
2 48 M 6 17.7 17.0 17.0 14.4 12.8 10.9 10.9 8.8 7.8 7.8 6.4 4.0 1 Nil + 
3 45 M 10 15.6 15.6 13.0 13.0 10.0 8.5 8.5 7.1 6.1 5.9 5.9 3.7 2 Nil + 
4 37 M 6 15.0 15.0 13.3 12.3 11.9 7.8 6.7 6.7 5.2 5.2 3.9 3.0 3 + + 
5 48 M 2 19.3 17.0 17.0 15.8 13.0 11.5 11.5 10.2 10.2 9.8 6.8 4.8 1.5 Nil Nil 
6 30 M 4 14.9 14.9 12.6 10.5 9.9 7.2 6.0 5.0 5.0 4.6 4.6 3.2 2.5 Nil Nil 
7 41 M 4 16.8 15.1 14.4 14.4 12.4 10.1 10.1 9.8 8.0 8.0 6.8 4.1 2 Nil + 
8 42 M 3 16.0 14.2 13.4 10.4 10.4 8.9 7.9 7.9 6.4 6.0 5.0 3.9 1 Nil + 
9 52 M 8 12.3 11.8 10.1 9.6 8.2 7.0 7.0 6.3 6.3 5.9 4.2 2.8 1.5 + + 
10 41 M 5 17.4 15.9 14.0 12.4 10.9 8.8 8.8 7.4 7.4 6.2 6.6 4.0 2.5 Nil + 
11 50 M 8 21.8 20.8 19.6 18.4 16.4 14.5 12.0 12.0 10.7 9.4 7.6 6.6 3 Nil + 
12 39 M 3 13.2 12.7 12.7 10.5 9.1 8.1 7.5 7.5 7.5 6.5 6.5 5.9 1.5 Nil Nil 
13 64 M 9 18.0 17.1 17.1 14.4 12.8 11.6 10.2 8.9 8.9 7.2 5.2 4.5 2 + + 
14 54 M 11 14.6 11.6 10.1 10.0 9.1 8.5 8.5 7.0 6.6 5.9 5.9 3.1 1.5 Nil + 
15 32 M 3 19.1 18.3 16.4 13.4 12.2 10.7 9.2 9.2 8.1 8.1 8.1 7.4 1.5 Nil Nil 
16 57 M 4 12.5 12.0 11.1 9.7 9.7 8.9 7.0 7.0 5.8 5.8 5.8 4.4 2 Nil + 
17 60 F 7 18.4 17.4 15.0 13.4 11.3 11.3 9.3 8.1 7.7 6.3 5.6 4.1 2 + + 
18 29 F 2 15.2 15.2 13.6 11.9 9.9 8.2 7.5 6.8 6.8 5.9 5.9 3.4 3 Nil Nil 
19 48 F 8 13.2 12.2 10.9 10.9 9.2 8.8 6.5 5.0 4.2 4.2 3.8 3.0 1.5 Nil + 
20 31 F 4 15.3 14.3 12.0 12.0 10.3 8.3 6.1 6.1 5.8 4.5 3.7 3.7 1 Nil Nil 
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AZATHIOPRINE (GROUP B) 
S.No Age Sex Duration of 
illness (yrs) 
P   A   S   I      S   C   O   R   E 
 
Remission 
in months 
Adverse 
effects 
Nail 
involve 
Ment W1 W2 W3 W4 W5 W6 W7 W8 W9 W10 W11 W12 
1 38 m 3 18.3 17.3 16.8 15.0 12.4 10.9 9.3 8.3 8.3 7.6 7.1 6.2 1.5 Nil Nil 
2 36 m 6 12.9 12.9 11.8 10.1 9.0 7.5 6.6 6.6 4.4 3.5 3.1 3.1 1 Nil + 
3 28 m 2 14.2 13.8 13.8 12.8 11.3 11.3 10.8 9.8 8.6 7.4 6.0 6.0 1 Nil Nil 
4 49 m 8 15.4 12.4 12.4 11.3 10.8 10.8 9.9 9.9 7.8 7.8 6.9 6.6 1.5 Nil + 
5 42 m 7 16.6 16.6 15.6 15.6 13.9 12.8 11.1 8.9 8.9 8.1 7.8 7.8 1 Nil + 
6 62 m 12 15.8 14.9 14.9 13.8 12.9 12.9 11.0 9.2 9.2 8.4 8.4 7.0 1 Nil + 
7 40 m 3 17.8 17.8 16.5 16.5 15.6 14.1 12.8 11.9 8.4 6.9 5.1 4.3 2 Nil Nil 
8 27 m 2 11.4 11.4 10.8 10.8 10.2 8.8 8.8 7.5 6.9 6.9 5.8 5.8 1 + Nil 
9 38 m 4 13.1 12.2 10.9 10.9 9.5 8.3 8.3 7.7 7.0 7.0 6.1 6.1 1.5 Nil + 
10 54 m 9 18.4 17.0 15.7 13.1 11.5 9.5 8.8 7.5 6.5 6.5 5.2 5.2 2 Nil + 
11 29 m 5 14.8 13.4 12.3 11.3 10.9 9.6 8.9 7.7 7.7 7.7 6.8 6.8 1.5 Nil + 
12 44 m 4 15.5 14.5 14.5 13.8 12.6 11.2 10.6 9.5 8.6 8.6 7.1 6.3 1 Nil + 
13 49 m 6 14.0 12.4 10.4 9.4 9.4 8.4 8.4 7.6 5.9 4.3 3.9 3.4 1 Nil + 
14 32 m 2 16.4 14.4 13.9 12.3 11.8 9.8 8.2 7.5 7.5 6.9 5.9 5.9 1 Nil Nil 
15 51 m 7 17.3 16.9 16.9 15.3 14.2 13.0 13.0 11.6 10.1 9.0 8.1 8.1 1 Nil + 
16 35 m 5 15.1 15.1 14.4 13.4 13.4 12.9 11.8 8.4 7.3 6.5 6.5 5.0 1.5 Nil + 
17 39 m 5 13.9 13.0 13.0 12.2 10.9 10.9 7.3 6.8 6.8 5.3 5.3 4.9 2 Nil + 
18 47 f 2 15.0 11.5 11.5 9.5 8.8 8.8 7.8 6.1 5.9 5.9 4.8 4.8 1.5 Nil Nil 
19 33 f 10 13.6 13.6 12.4 11.8 10.0 9.1 9.1 8.0 7.1 6.1 4.9 4.9 1 Nil + 
20 54 f 6 15.7 14.0 13.0 12.8 12.8 11.1 9.2 8.6 8.6 6.6 5.7 3.3 1.5 Nil + 
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